Publication | Open Access

Increased Tim-3+ T cells in PBMCs during nivolumab therapy correlate with responses and prognosis of advanced esophageal squamous cell carcinoma patients

Cancer ImmunosurveillanceEsophageal CancerMedicineImmunologyNivolumab Therapy CorrelateImmune Checkpoint InhibitorTim-3+ T CellsCancer TreatmentImmunotherapyOncologyRadiation Oncology